目的 探討寧泌泰膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療良性前列腺增生癥的臨床療效。方法 選取2018年6月—2020年3月在河南大學(xué)附屬鄭州頤和醫(yī)院就診的88例良性前列腺增生癥患者作為本研究對(duì)象，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各44例。對(duì)照組口服鹽酸坦索羅辛緩釋膠囊，0.2 mg/次，1次/d。治療組在對(duì)照組患者治療的基礎(chǔ)上口服寧泌泰膠囊，4粒/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的療效，比較兩組患者殘余尿量、前列腺體積、最大尿流率的變化及血清總前列腺特異抗原（tPSA）、胰島素樣生長因子-1（IGF-1）、轉(zhuǎn)化生長因子β₁（TGF-β₁）的水平，對(duì)患者的病情嚴(yán)重程度采用前列腺癥狀評(píng)分（IPSS）進(jìn)行評(píng)估。結(jié)果 治療后，治療組患者總有效率為93.18%，對(duì)照組總有效率為77.27%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的殘余尿量、前列腺體積顯著降低，最大尿流率顯著提高（P<0.05）；治療后，治療組的殘余尿量、前列腺體積低于對(duì)照組，最大尿流率高于對(duì)照組（P<0.05）。治療后，兩組的tPSA、IGF-1、TGF-β₁顯著降低（P<0.05）；治療后治療組的tPSA、IGF-1、TGF-β₁低于對(duì)照組（P<0.05）。治療后，兩組的IPSS評(píng)分顯著降低，治療組的IPSS評(píng)分較對(duì)照組降低的更明顯，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 寧泌泰膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療良性前列腺增生癥具有較好的臨床療效，可減輕臨床癥狀，調(diào)節(jié)tPSA、IGF-1、TGF-β₁的分泌。

Objective To explore the clinical effect of Ningmitai Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules in treatment of benign prostatic hyperplasia. Methods Patients (88 cases) with benign prostatic hyperplasia in Zhengzhou Yihe Hospital Affiliated to Henan University from June 2018 to March 2020 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Ningmitai Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and residual urine volume, prostate volume, maximum urine flow rate, and the levels of tPSA, IGF-1, and TGF-β₁ in two groups were compared. The severity of the disease in two groups was evaluated by IPSS scores. Results After treatment, the total effective rate of the treatment group was 93.18%, and that of the control group was 77.27%, and there was difference between two groups (P<0.05). After treatment, the residual urine volume and prostate volume of two groups were significantly reduced, and the maximum urinary flow rate was significantly increased (P<0.05). After treatment, the residual urine volume and prostate volume of the treatment group were lower than those of the control group, and the maximum urinary flow rate of the treatment group was higher than that of the control group (P<0.05). After treatment, the levels of tPSA, IGF-1, and TGF-β₁ in two groups were significantly decreased (P<0.05). After treatment, the levels of tPSA, IGF-1, and TGF-β₁ in the treatment group were lower than those in the control group (P<0.05). After treatment, the IPSS score of two groups was significantly decreased, and the IPSS score of the treatment group was more significantly lower than that of the control group (P<0.05). Conclusion Ningmitai Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules has clinical curative effect in treatment of benign prostatic hyperplasia, can relieve clinical symptoms, and regulate the secretion of tPSA, IGF-1 and TGF-β₁, which has good clinical application value.

R983

河南省衛(wèi)生健康科技英才海外研修工程項(xiàng)目（HWYX2019011）